Moderna, Inc. (MRNA)
Biological Products, (No Diagnostic Substances)
Latest Price
$135.61
TTM P/E
--
Normalized P/E
139.23
Div Yield
--
Book Value
17.07
P/B Ratio
7.94
Valuation metrics
adjust assumptions →Base FCF: $9.0B (median of recent 5yr)
Growth: 5%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$392.82
+190% upside
Institutional Ownership
87.5% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| FMR LLC | 51.86M | $3.63B | 13.00% | +6.19M | 2026-06-30 |
| BlackRock, Inc. | 30.60M | $2.14B | 7.67% | +963.5K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 23.21M | $1.63B | 5.82% | +336.3K | 2026-06-30 |
| Capital World Investors | 22.28M | $1.56B | 5.58% | +3.58M | 2026-06-30 |
| BAILLIE GIFFORD & CO | 18.21M | $1.27B | 4.56% | -1.78M | 2026-06-30 |
| STATE STREET CORP | 15.73M | $1.10B | 3.94% | +864.8K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 15.58M | $1.09B | 3.91% | -35.1K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 9.71M | $678.0M | 2.43% | +275.2K | 2026-06-30 |
| MORGAN STANLEY | 9.54M | $667.0M | 2.39% | +1.07M | 2026-06-30 |
| Theleme Partners LLP | 8.06M | $564.0M | 2.02% | +9.3K | 2026-06-30 |